PTO/SB/81 (01-09) Approved for use through 11/30/2011. OMB 0651-0035

Assymetric Disulfides and Methods o

7/10/03

1617

D. Lynn Kirkpatrick

Using Same

U.S. Patent and Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMS control number. 10/617,949 App. No. Filing Date

Title

First Named Inventor

POWER OF ATTORNEY OR REVOCATION OF POWER OF ATTORNEY WITH A NEW POWER OF ATTORNEY

AND CHANGE OF CORRESPONDENCE ADDRESS

Art Unit Shobha Kantamneni **Examiner Name** Attorney Docket Number 34395-725.501/Conf. No.4473 I hereby revoke all previous powers of attorney given in the above-Identified application. A Power of Attorney is submitted herewith. OR I hereby appoint Practitioner(s) associated with the following Customer 021971 Number as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith: OR I hereby appoint Practitioner(s) named below as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith: Registration Number Practitioner(s) Name Please recognize or change the correspondence address for the above-Identified application to: The address associated with the above-mentioned Customer Number. 021971 The address associated with Customer Number: Firm or Individual Name Address Zip State City Country Email

Telephone I am the:

Applicant/Inventor. OR

Assignee of record of the entire Interest. See 37 CFR 3.71. Ø

Statement under 37 CFR 3.73(b) (Form PTO/SB/96) submitted herewith or filed on

/ SIGNATURE of Applicant or Assignee of Record Date Signature Telephone Robert L. Kirkman, M.D. Name President and CEO for and on behalf of Prolx Pharmaceuticals Corp., a wholly-owned subsidiary

Title and Company of Oncothyreon Inc.

NOTE: Signatures of all the inventors or assignees of record of the entire Interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below

forms are submitted. *Total of

This collection of Information is required by 37 CFR 1.31, 1.32 and 1.33. The Information is required to obtain or retain a bonefit by the public which is to file (and by the 1.5PTCI is success) we application. Carefullusity is governed by 39 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to tail at 3 min of the 1.5PTCI is success) we application. Carefullusity is governed by 39 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to tail at 3 min of the 1.5PTCI is successful with a successful collection. The 1.5PTCI is successful with a successful collection of the 1.5PTCI is successful to the 1.5PTCI is successfu ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 07/319/21 Approved for use

	STATE	MENT U	NDER 37 CFR 3.73(b)	
Applicant/Patent Own	er: D. Lynn Kirkpatrick			
Application No./Pater	t No.: 10/617,949	Filed/l	ssue Date: 7/10/03	
Entitled: Asymmetric	Disulfides and Methods of Using	Same		
Prolx Pharmaceutic (Name of Assignee)	cals Corporation.	_,a <u>Per</u> (Tyr	nnsylvania corporation pe of Assignee, e.g., corporation, partne	rship, university, government agency, etc.)
states that it is the as	signee of the entire right, title, ar	d interes	it in;	
A. An assignn	nent from the inventor(s) of the p	atent app Office at	olication/patent identified above Reel , Frame, or for which a co	. The assignment was recorded py thereof is attached.
				, to the current assignee as follows:
4 5	Prolx Pharmaceuticals, Inc.		To: Proix Pharmaceuticals	Corp.
1. From:	The document was recorded in	the Unite	d States Patent and Trademark	Office at
	Reel 021604, Frame _0805	, or fo	r which a copy thereof is attach	ed.
	D. Lynn Kirkpatrick		To: Prolx Pharmaceuticals	
2. From:	Garth Powis The document was recorded in	the Unite		
	Reel 014878 , Frame 0426	, or fo	r which a copy thereof is attach	ed.
			To:	
3. From:	The document was recorded in	the Unite		c Office at
	Reel Frame or for which a cop	y thereof	is attached.	
Additional d	ocuments in the chain of title are			
				the original owner to the assignee was
	ate copy (i.e., a true copy of the as 7 CFR Part, 3, to record the as		term ((a)tnominob tnomino	be submitted to Assignment Division in See MPEP 302.08]
	hose tilly is supplied below) is au			nisho
Signature	e V			Date
•			Prolx F	ent and CEO for and on behalf of Pharmaceuticals Corp., a wholly-
Robert L. Kirkr	nan, M.D.		owned	I subsidiary of Oncothyreon Inc. Title
	r Typed Name			riuo

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 162 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including pathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this time and trademark Office. U.S. Patent and Trademark Office. U.S. Department of Commerce, P.O. Box 400 Applications, V.Z. 2313-1450, D. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Potentia, F.O. Box 1459, Alexandria, V.Z. 2313-1450.

PTO/SB/81 (01-09)

Approved for use through 11/30/2011. OMB 0651-0035 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Papenvork Reduction Act of 1995, no persons are require

POWER OF ATTORNEY OR REVOCATION OF POWER OF ATTORNEY WITH A NEW POWER OF ATTORNEY AND

CHANGE OF CORRESPONDENCE ADDRESS

o to respond to a collection of infi	ormation unless it displays a valid OMB control numbers				
App. No.	10/617,949				
Filing Date	7/10/03 D. Lynn Kirkpatrick				
First Named Inventor					
	Asymmetric Disulfides and Methods of Using Same				
Art Unit	1617				
Examiner Name	Shobha Kantamneni				
Attorney Docket Number	34395-725.501/Conf. No.4473				

I hereby revoke all previous powers of attorney given in the above-identified application.								
	A Power of Attorney is submitted herewith, OR							
⊠ a	Number as my/ identified above	tereby appoint Practitioner(s) associated with the following Customer unber as my/our attorney(s) or agent(s) to prosecute the application entified above, and to transact all business in the United States Patent dd Trademark Office connected therewith:						
		Practitioner(s) Name		Registration Number				
ŀ								
Pleas	Please recognize or change the correspondence address for the above-identified application to:							
	The address associated with the above-mentioned Customer Number.							
OR The address associated with Customer Number: 021971								
	Firm or Individual Name	0						
Addres	Address							
City				State		Zip		
Countr								
Teleph				Email	L			
l am the: Applicant/Inventor.								
OR Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b)-(Form PTO/SB/96) submitted herewith or filed on								
SIGNATURE of Applicant or Assignee of Record								
Signatu	ıre	Xetus > /	De S		Date	4.284	10	
Name		Patrick L. Jorles			Telephone	5900	24	5000
	d Company	Director, Office of Technology			University of Aria			
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.								
\boxtimes	Total of 2	forms are submitted.						

This constant of Information is required by 27 CFR 1.31, 132 and 1.33. The Information is required to obtain or retnin a benefit by the public which is to fit (and by the CFR 1.31, 132 and 1.33. The Information is required to obtain or retnin a benefit by the public which is the Information CFR 1.32 and 37 CFR 1.11 and 1.14, 132 to obtain or setting these informations considered application form to the USPTO. Time will vary depending upon the information confidence application form to the USPTO. Time will vary depending upon the information of the amount of time you require to complete this form and/ords suggestions for reducing this burder, should be sent to the Chief Information Officer, U.S. Peters and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandris, VA 22313-1450, DD NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandris, VA 22313-1450, DD NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandris, VA 22313-1450, DD NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandris, VA 22313-1450, DD NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandris, VA 22313-1450, DD NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandris, VA 22313-1450, DD NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent C	wner: D. Lynn Kirkpatrick				
Application No./Pa	ent No.: 10/617,949 Filed/Issue Date: 7/10/03				
Entitled: Asymmetr	ic Disulfides and Methods of Using Same				
Arizona Board of University of Ariz	Regents on behalf of the one of the state of Arizona				
(Name of Assignee)	(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)				
states that it is:					
1. X the assig	nee of the entire right, title, and interest in;				
	an assignee of less than the entire right, title and interest in (The extent (by percentage) of its ownership interest is%; or				
3. the assig	the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)				
in the patent applic	ation/patent identified above by virtue of either:				
in the Un attached	nment from the inventor(s) of the patent application/patent identified above. The assignment was recorded ted States Patent and Trademark Office at Real <u>018449</u> , Frame <u>0474</u> , or for which a copy thereof is				
	f title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:				
1. Fror	n:To:				
	The document was recorded in the United States Patent and Trademark Office at				
	Reel, Frame, or for which a copy thereof is attached.				
2. Fror	To:				
	The document was recorded in the United States Patent and Trademark Office at				
	Reel, Frame, or for which a copy thereof is attached.				
2 Eror	To:				
3.1101	The document was recorded in the United States Patent and Trademark Office at				
	Reel, Frame, or for which a copy thereof is attached.				
Additional	documents in the chain of title are listed on a supplemental sheet(s).				
As required by or concurrently	37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, is being, submitted for recordation pursuant to 37 CFR 3.11.				
[NOTE: A sepa accordance wi	rate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in h 37 CFR Part 3, to record the assignment in the records of the USPTO. <u>See</u> MPEP 302.08]				
The undersigned (hose title is supplied below) is authorized to act on behalf of the assignee.				
Signatu	Date				
Patrick L. Jon	District Control of Transaction Transaction				
Printed	or Typed Name Title				

This collection of information is required by 37 CFR 3.73(b). The Information is required to Johan or retain a benefit by the public which is to fit (and by the USPTO) to process) an application. Confidentially is government by JUS and 37 CFR 1.1 and 37 CFR 1.1 and 3.1 A fits achesions in estimated to bit immutes to complete, including process and support of the public public process and the public process and the public process and the public public process and the public process and the public publi